Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
RBR-84sdd6Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Brivanib arm with Sorafenib control arm (2 arms). Started May 2010; status: recruiting.
02
Drugs
brivanibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on RBR-84sdd6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-84sdd6.